# Differentiated Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/differentiated-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.dxtherapeutics.com
- Total disclosed funding: $5M
- Latest round: Seed (Aug 1, 2022)
- Investors on record: 1

## About

Based in California, US, and founded in 2021 by CEO Bryce Allen, COO Diala Ezzeddine, and co-founder Isaac Kohane, Differentiated Therapeutics, Inc. operates as a developer of computationally predicting and optimizing targeted protein degraders (TPDs) and transformative medicines. In August 2022, Curie.Bio led USD 5 million in seed funding for Differentiated Therapeutics, Inc. 

Differentiated Therapeutics, Inc. designs and develops disease modifying TPD therapies for patients with unmet medical needs. The company offers targeted protein degradation (TPD), a novel protein degrader, to eliminate the genetically defined drivers of disease. In addition, the firm provides an automatic differentiation (Auto/dx) platform, a collection of tools that enable differentiable portfolio planning by screening a differentiated therapeutic knowledge graph (DTKG) to identify protein degradation strategies for targets with indications of high unmet needs.

## Funding rounds

- Seed, Aug 1, 2022, $5M — Curie.Bio

## Investors

- Curie.Bio (https://capitalatlas.ai/funds/curie-bio) — Seed